Treatment options in renal cell carcinoma: past, present and future.
Journal Article (Journal Article;Review)
Cytokine therapies have been the standard of care in metastatic renal cell carcinoma (RCC). However, these agents only provide clinical benefit to a small subset of patients and are associated with significant toxicity. A better understanding of the molecular biology of RCC has identified the vascular endothelial growth factor (VEGF) and platelet-derived growth factor signalling pathways as rational targets for anticancer therapy. The multitargeted receptor tyrosine kinase inhibitors sunitinib and sorafenib have both demonstrated improved efficacy as second-line therapy in patients with RCC. Sunitinib has also been shown to be effective in the first-line setting, and has recently received European Union approval as first-line treatment for advanced and/or metastatic RCC. There is also recent evidence that temsirolimus (an inhibitor of the mammalian target of rapamycin) and bevacizumab (a mAb targeted against VEGF) may provide benefits in the first-line treatment setting. These results confirm that inhibiting these tumour targets is a feasible approach to treatment and provides a more positive outlook for the future management of metastatic RCC.
Full Text
Duke Authors
Cited Authors
- Oudard, S; George, D; Medioni, J; Motzer, R
Published Date
- September 2007
Published In
Volume / Issue
- 18 Suppl 10 /
Start / End Page
- x25 - x31
PubMed ID
- 17761720
International Standard Serial Number (ISSN)
- 0923-7534
Digital Object Identifier (DOI)
- 10.1093/annonc/mdm411
Language
- eng
Conference Location
- England